Trial Profile
A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 25 Oct 2022
Price :
$35
*
At a glance
- Drugs Penpulimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Akesobio Australia
- 20 Oct 2022 Planned End Date changed from 1 Jun 2020 to 1 Oct 2023.
- 20 Oct 2022 Planned primary completion date changed from 1 Dec 2019 to 1 Sep 2023.
- 20 Oct 2022 Status changed from recruiting to active, no longer recruiting.